# An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B

> **NCT02554773** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 34 (actual)

## Conditions studied

- Hemophilia A
- Hemophilia B

## Interventions

- **DRUG:** Fitusiran (SAR439774)

## Key facts

- **NCT ID:** NCT02554773
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-18
- **Primary completion:** 2023-03-21
- **Final completion:** 2023-03-21
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02554773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02554773, "An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT02554773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*